SCHEMBL4889438

SCHEMBL4889438

CC(=O)/C(=C/c1ccc(Cl)c(Cl)c1)C(=O)NCCCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.49
RAB9A P51151 4/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
ALDH1A1 P00352 3/20 0.49
EGFR P00533 3/20 0.49
KMT2A Q03164 3/20 0.49
MAPT P10636 3/20 0.49
KDM4E B2RXH2 2/20 0.49
MEN1 O00255 2/20 0.49
CYP1A2 P05177 2/20 0.49
CYP3A4 P08684 2/20 0.49
CYP2D6 P10635 2/20 0.49
HPGD P15428 2/20 0.49
ALOX15 P16050 2/20 0.49
ALOX12 P18054 2/20 0.49
MAPK1 P28482 2/20 0.49
CYP2C19 P33261 2/20 0.49
RECQL P46063 2/20 0.49
BLM P54132 2/20 0.49
HSD17B10 Q99714 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4491589 1.00 LMNA (0.49) LMNARAB9ASMN1; SMN2ALDH1A1EGFR
SCHEMBL4899806 0.97 EGFR (0.50) LMNARAB9ASMN1; SMN2ALDH1A1EGFR
SCHEMBL4488945 0.97 EGFR (0.50) LMNARAB9ASMN1; SMN2ALDH1A1EGFR
SCHEMBL4891620 0.93 LMNA (0.57) LMNARAB9ASMN1; SMN2ALDH1A1EGFR
SCHEMBL4498599 0.93 LMNA (0.57) LMNARAB9ASMN1; SMN2ALDH1A1EGFR
SCHEMBL4512306 0.88 APOBEC3A (0.54) LMNARAB9ASMN1; SMN2ALDH1A1EGFR
SCHEMBL4503995 0.88 APOBEC3A (0.54) LMNARAB9ASMN1; SMN2ALDH1A1EGFR
SCHEMBL4517907 0.87 LMNA (0.55) LMNARAB9ASMN1; SMN2ALDH1A1EGFR
SCHEMBL4898673 0.87 LMNA (0.55) LMNARAB9ASMN1; SMN2ALDH1A1EGFR
SCHEMBL4900705 0.86 ALDH1A1 (0.53) LMNARAB9ASMN1; SMN2ALDH1A1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080070903-A1 NEW PYRIMIDINE DERIVATIVES AND NEW PYRIDINE DERIVATIVES AJINOMOTO CO., INC (JP) 2008-03-20 US disclosed
US-6855716-B2 Dihydropyrimidine compounds and compositions containing the same AJINOMOTO CO., INC. (JP) 2005-02-15 US disclosed
US-20020143023-A1 Dihydropyrimidine compounds and compositions containing the same AJINOMOTO CO. INC (JP) 2002-10-03 US disclosed
EP-1193259-A1 DIHYDROPYRIMIDINE DERIVATIVES Ajinomoto Co., Inc. (JP) 2002-04-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143023-A1 Dihydropyrimidine compounds and compositions containing the same CACNA1B, CACNA1D, CACNA1G LMNA 1538/4885RAB9A 2075/4885SMN1; SMN2 350/4885
US-20080070903-A1 NEW PYRIMIDINE DERIVATIVES AND NEW PYRIDINE DERIVATIVES P2RY10, CACNA1B, CACNA1E LMNA 3830/4885RAB9A 1373/4885SMN1; SMN2 758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.